Products with Estrogen receptor agonists bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN1130 | trans-Hinokiresinol |
| 1. Hinokiresinol (trans-hinokiresinol) and nyasol (cis-hinokiresinol) possess appreciable estrogen receptor binding activity, they can stimulate the proliferation of estrogen- dependent T47D breast cancer cells, and their stimulatory effects could be blocked by an estrogen antagonist, indicating that they are estrogen agonists. 2. trans- and cis-Hinokiresinols have similar free radical scavenging and anti-inflammatory activities, they also have anti-ischemic effects, only trans-hinokiresinol can significantly decrease neuronal injury in cultured cortical neurons exposed to oxygen-glucose deprivation followed by re-oxygenation. 3. Hinokiresinol is a novel inhibitor of LTB4 binding to the human neutrophils. 4. Hinokiresinol has antiallergic effect, it inhibits IgE-induced mouse passive cutaneous anaphylaxis reaction. | |
| BCN4509 | Guajadial |
| 1. Guajadial, psidial A and psiguadials A and B can reduce tumor growth and stimulate uterus proliferation, suggest that they may act as Selective Estrogen Receptors Modulators (SERMs), therefore holding significant potential for anticancer therapy. 2. Guajadial shows α-glucosidase inhibitory activities significantly and its activity was better than that of Acarbose. 3. Guajadial exhibits potent inhibitory effects on the growth of human hepatoma cells. | |
| BCN5241 | Medicarpin |
| 1. Medicarpin, a legume phytoalexin, acts as an estrogen receptor (ER) agonist, can stimulate osteoblast differentiation likely via ERβ, promote achievement of peak bone mass, and is devoid of uterine estrogenicity; in addition, given its excellent oral bioavailability, it can be potential osteogenic agent. 2. Medicarpin exhibits no uterine estrogenicity, however it can inhibit osteoclastogenesis and has nonestrogenic bone conserving effect in ovariectomized mice. 3. Medicarpin and maackiain and two of their biosynthetic precursors inhibit the constitutive and phenobarbital (PB)-induced types of AHH, but have little effect on the 3-methylcholanthrene (MC)-induced type of AHH. 4. Medicarpin sensitizes myeloid leukemia cells to TRAIL-induced apoptosis through the induction of DR5 and activation of the ROS-JNK-CHOP pathway. 5. Medicarpin has antifungal activity. | |
| BCN5414 | Psoralidin |
| Psoralidin possesses potent antidepressant-like, anti-inflammatory, anticancer and chemopreventive properties. Psoralidin is a dual inhibitor of COX-2 and 5-LOX, it is also an agonist for both estrogen receptor (ER)α and ERβ agonist.Psoralidin inhibits LPS-induced iNOS expression via repressing Syk-mediated activation of PI3K-IKK-IκB signaling pathways, it induces reactive oxygen species (ROS)-dependent DNA damage and protective autophagy mediated by NOX4 in breast cancer cells. | |
